The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1180-1185 , December 2009

Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma

  • Tari Haahtela, MD, PhD

      Affiliations

    • Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland
    • Corresponding Author InformationReprint requests: Tari Haahtela, MD, PhD, Skin and Allergy Hospital, Helsinki University Central Hospital, PO Box 160, 00029 HUS, Finland.
    • ,
  • Klaus Tamminen, MD

      Affiliations

    • Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Tuomo Kava, MD, PhD

      Affiliations

    • Northern-Karelia Central Hospital, Joensuu, Finland
    • ,
  • L. Pekka Malmberg, MD, PhD

      Affiliations

    • Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Paula Rytilä, MD, PhD

      Affiliations

    • Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Kurt Nikander, BA

      Affiliations

    • Respironics, Parsippany, NJ
    • AstraZeneca R&D, Lund, Sweden
    • ,
  • Tore Persson, PhD

      Affiliations

    • AstraZeneca R&D, Lund, Sweden
    • ,
  • Olof Selroos, MD, PhD

      Affiliations

    • Semeco, Ängelholm, Sweden

Received 23 April 2009 ,Revised 16 September 2009 ,Accepted 21 September 2009.

  • Image Result

    Flow chart of management of the patients from the initial random assignment to 2 groups to the 13-year follow-up examination. pMDI, Pressurized metered-dose inhaler; TBH, Turbuhaler.

    Flow chart of management of the patients from the initial random assignment to 2 groups to the 13-year follow-up examination. pMDI, Pressurized metered-dose inhaler; TBH, Turbuhaler.

  • Image Result

    Left, Hospital days/year during the past 10 years and drug costs/year during the past 7 years. Middle, β2-agonists and subjective change from baseline in asthma severity during the last year. Right, A

    Left, Hospital days/year during the past 10 years and drug costs/year during the past 7 years. Middle, β2-agonists and subjective change from baseline in asthma severity during the last year. Right, Asthma symptom scores during the last month and use of ICSs (μg/d) in patients treated early with inhaled budesonide or after a 2-year delay. Mean values and SEMs are shown.

 Supported by grants from Helsinki University Central Hospital (grant 2303), AstraZeneca, Finland, and AstraZeneca R&D, Lund, Sweden.

 Disclosure of potential conflict of interest: T. Haahtela receives honoraria from ALK-Abelló, AstraZeneca, Meda Oy, MSD, and Orion Pharma; is on the advisory board for MSD and Orion Pharma; and receives grant support from Orion Diagnostics and Stallergenes. K. Tamminen was employed by AstraZeneca Finland until June 2009. T. Kava receives lecture fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and MSD and receives financial support for attending meetings from Boehringer Ingelheim. P. Rytilä is employed by Orion Pharma. K. Nikander is employed by Philips Respironics. T. Persson is employed by and is a shareholder in AstraZeneca R&D. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01437-7

doi: 10.1016/j.jaci.2009.09.036

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1180-1185 , December 2009

Article Tools

* Image Usage & Resolution